Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 31 Jul 2024
Deaths from non-melanoma skin cancers have almost doubled in Australia this millennium?and the culprit is hiding in plain sight, according to new medical research led by the University of the Sunshine Coast.
Read Full NewsComplicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.
A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.
The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.
1.
More Positive Survival Data in Lung Cancer With Perioperative Therapy
2.
Good News for CAR-T Therapy; Liquid Biopsy Progress; Anti-Psychotic for Brain Cancer
3.
Sickle Cell Disease Drug Pulled From Global Markets
4.
Biomarker panel offers hope for early pancreatic cancer detection
5.
Having dense breasts is linked to cancer, but advice about breast density can depend on where you live
1.
Acrochordon: What It Is, Causes, And How To Manage This Skin Condition
2.
Understanding Thrombin Time: What It Is and How It Can Help Diagnose Blood Clotting Disorders
3.
Unlocking the Mysteries of ICD 10 Code Normocytic Anemia
4.
The latest research on Iron Binding Capacity: The Little-Known Factor That Could Impact Your Health v
5.
Emerging and Innovative Therapies in Cancer Treatment and Post-Surgical Care
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
5.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge